Table 2.
Demographic and Epidemiologic Characteristics of the Study Population (NDV-3A vs. Placebo).
| Subject Characteristic | NDV-3A (N = 189)a | Placebo (N = 191)a | Distribution bv Training Companv | |||
|---|---|---|---|---|---|---|
| Cohort A (N = 82)a | Cohort B (N = 120) | Cohort C (C = 89) | Cohort D (N = 89) | |||
| Median (range) age, years | 20 (17–35) | 20 (17–34) | 20 (17–32) | 20 (18–31) | 19 (18–35) | 20 (18–34) |
| Ethnicity, Number (%) | ||||||
| Not Hispanic or Latino | 152 (80.42) | 146 (76.44) | 64 (78.05) | 93 (77.50) | 70 (78.65) | 71 (79.78) |
| Hispanic or Latino | 37 (19.58) | 45 (23.56) | 18 (21.95) | 27 (22.50) | 19 (21.35) | 18 (20.22) |
| Race, Number (%) | ||||||
| American Indian or Alaska Native | 0 (0) | 1 (0.52) | 0 (0) | 0 (0) | 0 (0) | 1 (1.12) |
| Asian | 4 (2.12) | 3 (1.57) | 0 (0) | 1 (0.83) | 3 (3.37) | 3 (3.37) |
| Native Hawaiian or Other Pacific Islander | 2 (1.06) | 1 (0.52) | 1 (1.22) | 1 (0.83) | 0 (0) | 1 (1.12) |
| Black or African American | 19 (10.05) | 19 (9.95) | 8 (9.76) | 8 (6.67) | 8 (8.99) | 14 (15.73) |
| White | 145 (76.72) | 144 (75.39) | 60 (73.17) | 99 (82.50) | 68 (76.40) | 62 (69.66) |
| Multi-Racial | 8 (4.23) | 8 (4.19) | 5 (6.10) | 4 (3.33) | 3 (3.37) | 4 (4.49) |
| Unknown | 11 (5.82) | 15 (7.85) | 8 (9.76) | 7 (5.83) | 7 (7.87) | 4 (4.49) |
| Known/suspected skin infection or MRSA infection in past 12 monthsb | 1 (0.54) | 1 (0.53) | 0 (0) | 0 (0) | 2 (2.25) | 0 (0) |
| Contact with a person with known /suspected skin infection or MRSA infection in past 3 monthsb | 1 (0.54) | 3 (1.59) | 0 (0) | 1 (0.87) | 3 (3.37) | 0 (0) |
| Antibiotic use in the past 6 monthsb | 7 (3.78) | 8 (4.26) | 4 (4.88) | 7 (6.09) | 2 (2.25) | 2 (2.30) |
a
Two subjects were excluded from all analyses due to treatment vial mix-up, resulting in that NDV-3A versus Placebo administration could not be determined for the two subjects who were vaccinated on the same date around the same time.
b
Among those who responded to these particular questions (185 from the NDV-3A group, 188 from the placebo group).